A new blood test designed to detect over 50 cancers has divided doctors on whether it is worth the risks for patients. Breast cancer mortality rates between Black and white women in America show persistent racial disparities. Researchers are finding that getting Black and Hispanic people into clinical trials is not enough to eliminate disparities. A study reveals that oncologists are more likely to provide low-value cancer care after receiving money from pharmaceutical companies. 23andMe is launching a new product to help customers understand and manage health risks hidden in their DNA.
23andMe is rolling out a new product to help customers better understand and manage health risks hidden in their DNA https://t.co/Y7jVJceUsp
For $1,200, 23andMe wants to tell you the health risks lurking in your DNA https://t.co/DoNKppRzE6
Cancer disparities persisted even among clinical trial participants, study finds. https://t.co/wkQLCSWQyr
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, according to a new study. https://t.co/pXozPg78ns
Getting Black and Hispanic people into clinical trials has been a mission for researchers. But a new study shows it isn’t enough to erase disparities. https://t.co/hVE1E1xLmH
As breast cancer deaths decline in America, racial disparities persist in the mortality rates between Black and white women. https://t.co/IemuvK7pm1 https://t.co/x7K85l3wEO
This $1,000 blood test is designed to detect more than 50 cancers. Doctors are split on whether it is worth the risks for patients. https://t.co/6RM2MWhNjR
For Breast Cancer, 40 Is the New 50 https://t.co/EWXpzQ9ub7
The new blood test is designed to detect more than 50 cancers. Doctors are split on whether it is worth the risks for patients. https://t.co/7uUlDNshZj https://t.co/5s05FtnCeO